Table 1 |
|||
|
Medications taken by OA patients (n = 39), by all RA patients (n = 79) and by RA patients in whom insulin sensitivity was determined (n = 39) |
|||
| Medication |
OA (n = 39) |
RA (n = 79) |
RA (n = 39) |
|
|
|||
| Antihypertensives |
10 (26) |
18 (23) |
8 (21) |
| Estrogen |
6 (15) |
6 (8) |
2 (5) |
| NSAID |
14 (36) |
33 (42) |
17 (44) |
| Low efficacy opioids |
3 (8) |
5 (6) |
2 (5) |
| Paracetamol |
3 (8) |
4 (5) |
3 (8) |
| Thyroxine |
2 (5) |
2 (3) |
0 (0) |
| Glucosamine |
2 (5) |
3 (4) |
0 (0) |
| Omeprazole |
1 (3) |
0 (0) |
0 (0) |
| DMARD |
0 (0) |
42 (53)* |
19 (49) |
| Prednisone |
0 (0) |
10 (13)** |
6 (15) |
| Amitryptiline |
0 (0) |
2 (3) |
0 (0) |
| Zopiclone |
0 (0) |
3 (4) |
0 (0) |
| Metformin |
0 (0) |
1 (1) |
0 (0) |
| Gliclazide |
0 (0) |
3 (4) |
2 (5) |
| Insulin |
0 (0) |
1 (1) |
0 (0) |
| Fluoxetine |
0 (0) |
1 (1) |
1 (3) |
| Clonazepam |
0 (0) |
3 (4) |
0 (0) |
|
|
|||
|
Data presented as n (%). NSAID, nonsteroidal anti-inflammatory agents; DMARD, disease-modifying agents. * Agents were methotrexate (n = 37), chloroquine (n = 17), minocyclin (n = 6), sulphasalazine (n = 4), azathioprine (n = 4), and myocrysin (n = 2). ** Median dose was 5 mg daily (range, 3–20 mg). |
|||
|
Dessein et al. Arthritis Res 2002 4:R5 doi:10.1186/ar428 |
|||
